Comment by sniperjoe360

Really impressive results. The real victory here wasn't the breakthrough drug, which many have pointed out is another flavor of PD-1 inhibition (Nivolumab, Pembro) It's the patient selection - careful curation of MSI status with Next Gen Sequencing. Clinically it has already been implemented and is changing the outcomes of thousands of patients every year.